Specialty Chemicals and Materials: Formulation-Based vs. Commodity

Introduction

Specialty chemicals and materials is a sub-sector within specialty industrials where the single most important analytical decision is classification: is the company a formulation-based specialty business (high margins, pricing power, premium multiple) or a commodity chemical producer (volatile margins, no pricing power, cyclical multiple)? This distinction matters more for valuation than any other variable, including revenue size, end-market exposure, or geographic mix. A formulation-based adhesive company and a commodity polyethylene producer may both be classified as "chemicals," but they operate under fundamentally different economic models and deserve fundamentally different valuation multiples.

The global specialty chemicals market is valued at approximately $1.1-1.4 trillion in 2025, growing at an estimated 3-5% annually. Companies like Ecolab (which posted record fiscal 2025 results with $16 billion in sales and 18.5% operating margins), Sika (material margin of 54.9% in 2025), and RPM International demonstrate the premium economics that formulation-based businesses can achieve. For industrials bankers, understanding what creates "formulation value" and how to identify it during due diligence is essential for correctly positioning chemical companies on the valuation spectrum.

Formulation Value

The economic premium that a specialty chemical company earns because customers pay for the performance characteristics of a blended, proprietary product rather than the cost of its raw material inputs. A water treatment chemical formulation might cost $3 per pound in raw materials but sell for $15 per pound because the customer values the performance (scale prevention, corrosion inhibition, biological control) rather than the molecules themselves. This performance premium creates pricing power that persists even when raw material costs fluctuate, because the value to the customer is independent of the input cost. Formulation value is the fundamental driver of specialty chemical margins and the primary source of the valuation premium over commodity chemicals.

Formulation-based specialty chemicals share several characteristics that create and protect their margin premium.

Application-specific formulation. The product is designed to solve a specific problem in a specific application (cleaning a particular type of industrial equipment, bonding a particular combination of substrates, coating a surface to meet specific performance criteria). The recipe is proprietary, tested, and qualified by the customer. Switching to an alternative formulation requires re-qualification testing, which creates switching costs.

Technical service and support. Specialty chemical companies do not just sell products; they provide application engineering, technical support, dosing optimization, and performance monitoring. Ecolab's water treatment business, for example, includes on-site technical service representatives who optimize chemical dosing, monitor water quality, and ensure compliance with environmental regulations. This service layer deepens the customer relationship and makes the total value proposition difficult to replicate with a commodity substitute.

Cost is small relative to customer operations. The specialty chemical typically represents a tiny fraction of the customer's total operating cost but protects against a disproportionately large risk (equipment failure, product quality rejection, regulatory non-compliance). This cost asymmetry creates meaningful pricing insensitivity: the customer will not switch suppliers to save 10% on a chemical that represents 0.1% of total operating costs but protects against millions in potential losses.

The formulation vs. commodity classification directly affects how bankers approach chemical companies in M&A and valuation work.

Comp set construction. The most common analytical error in chemicals is blending specialty and commodity companies into a single comp set. A specialty adhesive company (12-18x EBITDA) should not be comped against commodity resin producers (5-8x), even though both are "chemical" companies. Correctly identifying which tier a company belongs to is the most impactful analytical decision in a chemicals sell-side process.

Sell-side narrative. For specialty chemical sell-sides, the banker's key analytical work is demonstrating formulation value: documenting the proprietary recipe, quantifying switching costs, showing raw material pass-through history, and demonstrating the cost-to-customer-benefit asymmetry. Every element of the CIM should reinforce the message that the company sells performance, not molecules.

M&A dynamics. Specialty chemicals M&A is driven by three primary themes. Portfolio reshaping by large diversified companies divesting non-core specialty lines creates sell-side mandates at bulge bracket banks. PE consolidation of fragmented niches (specialty adhesives, coatings, water treatment chemicals, specialty lubricants, personal care chemicals) creates roll-up deal flow at middle-market banks. And strategic acquisitions by serial acquirers (BASF, Sherwin-Williams, H.B. Fuller, Sika) seeking to add formulation-based businesses to their portfolios drive buy-side advisory mandates. The specialty chemicals market's fragmented structure, with thousands of small formulation companies serving niche applications around the world, creates one of the most consistent roll-up deal pipelines in all of industrials banking. The European specialty chemicals landscape is particularly active for M&A, with companies like Sika (Switzerland), Arkema (France), and Evonik (Germany) serving as both acquirers and divestiture candidates in an ongoing reshaping of the global specialty chemicals map.